RxDoctor Payments Data

Gwendoline Fonebi, MD

Medical Oncology · Pocatello, IDNPI 1184911141

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $482 of the $675 with a category attached, or 71.4%. It is spread thinly across 15 manufacturers, the largest accounting for just 14.7%.

$675in general payments, 2019–2025

Across 28 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$99
  • AbbVie$83
  • GSK$75
  • Amgen$74
  • Novartis$65
  • Bristol Myers Squibb$65
  • plus $215 from 9 others

What the payments were for

  • Food & beverage$48271%
  • Education$19329%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few medical oncology providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$79,764
Medicare patients
369
Services billed
787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate33$438,946
RevlimidLenalidomide24$436,385
Lenalidomide22$315,358
TagrissoOsimertinib Mesylate17$257,947
BrukinsaZanubrutinib16$237,447
LonsurfTrifluridine/Tipiracil Hcl12$147,936
VenclextaVenetoclax13$103,206
XareltoRivaroxaban59$86,156
ZenpepLipase/Protease/Amylase16$40,468
EliquisApixaban33$26,323
ValacyclovirValacyclovir Hcl37$1,833
Letrozole62$929
Hydroxyurea27$791
Pantoprazole Sodium50$602
Dexamethasone28$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$65$436,38524 claims
AbbVieVenclexta$83$103,20613 claims
Johnson & JohnsonXarelto$19$86,15659 claims
PfizerEliquis$51$26,32333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other medical oncology in Pocatello

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →